Safety, Tolerability, and Pharmacokinetics Study of ATH-1020

Phase 1 Completed 32 enrolled LeonaBio Alturas Analytics, Inc. · collab Biotrial Inc. · collab

RandomizedSequentialQuadruple-blindTreatment

Summary

This Phase 1 randomized, placebo-controlled, double-blinded, first-in-human study will evaluate safety, tolerability, and pharmacokinetics of single and multiple ascending doses of ATH-1020 in healthy young and elderly subjects.

Timeline

Start: 2022-03-30
Primary completion: 2022-09-09
Completion: 2022-09-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ATH-1020	Unknown	—	Oral

Indications

No indication recorded.